Skip to content

Clinical trials

Observational Postoperative Complications trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Postoperative Complications Phase: Observational Country / region: China Clear all

62 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20071
20092
20131
20141
20153
20163
20184
20196
20204
20214
20226
20239
20246
20255
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed27
Unknown status15
Recruiting12
Active, not recruiting5
Not yet recruiting2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Xijing Hospital5
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University3
Peking University First Hospital3
Beijing Tsinghua Chang Gung Hospital2
Chinese PLA General Hospital2
First Affiliated Hospital of Chongqing Medical University2
Peking Union Medical College Hospital2
Peking University Third Hospital2
Ruijin Hospital2
The Second Affiliated Hospital of Chongqing Medical University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Postoperative Complications62
COVID-195
Stomach Neoplasms4
Acute Kidney Injury3
Breast Neoplasms3
Esophageal Squamous Cell Carcinoma3
Rectal Neoplasms3
Anastomotic Leak2
Cardiomyopathy, Hypertrophic2
Cognitive Dysfunction2

Trials

Showing 1 to 25 of 62. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.